Login
$RVMD
$166.04 After hours

Company Executives

Officer Age In this role 2025 pay Source
Jack Anders
Chief Financial Officer
49 Since 2022
4 years
$3,588,111
Margaret Horn
Chief Operating Officer
63 Since 2018
8 years
$4,821,057
Alan Sandler, M.D.
Chief Development Officer
69 Since 2025
1 year
Not reported
Jeffrey Cislini
Senior Vice President, General Counsel and Secretary
51 Since 2022
4 years
$3,718,589
Stephen M. Kelsey, M.D., FRCP, FRCPath
President, Research and Development
65 Since 2017
9 years
$5,963,229
Mark A. Goldsmith, M.D., Ph.D. Also a director
See Remarks
Title from the Form 4 dated Sep 16, 2026
64 Not stated $14,672,390
Anthony Mancini
See Remarks
Title from the Form 4 dated Nov 9, 2026
55 Not stated Not reported
Stephen Michael Kelsey
See Remarks
Title from the Form 4 dated Sep 16, 2026
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
0 of 1
stated in the proxy; 8 not stated
Average tenure
6.8 years
from year joined
CEO also chairs the board
Yes
Mark A. Goldsmith, M.D., Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Mark A. Goldsmith, M.D., Ph.D.
64 2014
12 years
Not independent None stated None stated Paid as CEO
Alexis Borisy
54 2014
12 years
Not stated None stated Relay Therapeutics, Inc. $481,225
Elizabeth McKee Anderson
68 2015
11 years
Not stated
Compensation Committee · Chair Commercialization Committee
GSK plc (NYSE: GSK) $461,620
Flavia Borellini, Ph.D.
66 2021
5 years
Not stated
Research and Development Committee · Chair
None stated $461,225
Lorence Kim, M.D.
52 2022
4 years
Not stated
Nominating and Corporate Governance Committee · Chair
Cencora, Inc. (NYSE: COR) $468,329
Frank K. Clyburn, Jr.
61 2024
2 years
Not stated
Commercialization Committee · Chair
Kailera Therapeutics, Inc. (Nasdaq: KLRA) $419,497
Sandra J. Horning, M.D.
77 2023
3 years
Not stated
Research and Development Committee
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) $445,829
Sushil Patel, Ph.D.
55 2022
4 years
Not stated None stated None stated $455,829
Thilo Schroeder, Ph.D.
45 2018
8 years
Not stated None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support